4.7 Article

Smoking is a risk factor for recurrence of intestinal stricture after endoscopic dilation in Crohn's disease

Journal

ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 37, Issue 4, Pages 430-437

Publisher

WILEY
DOI: 10.1111/apt.12176

Keywords

-

Funding

  1. Foundation for Clinical Research in Inflammatory Bowel Disease, United States
  2. Uppsala-Orebro Regional Research Council, Sweden

Ask authors/readers for more resources

Background Endoscopic balloon dilation is an efficacious and safe alternative to surgery as treatment of short intestinal strictures in Crohn's disease (CD). Factors predicting outcome of the procedure are not well described. Aim To evaluate whether smoking at diagnosis, treatment with azathioprine, or other clinical variables may affect clinical outcome after endoscopic dilation. The endpoint was requirement of a new intervention such as dilation or surgery with intestinal resection or strictureplasty. Methods Retrospective study of 83 patients with CD who underwent endoscopic balloon dilation of an intestinal stricture between 1987 and 2009. Results After index dilation 55/83 patients underwent a new intervention. Among current smokers, 31/32 (97%) underwent another intervention compared to 18/33 (55%) among never smokers (adjusted HR: 2.50, 95% CI: 1.145.50, P = 0.022). After 5 years, cumulative probability of new intervention was 0.81 in smokers compared to 0.52 in never smokers; difference 0.29 (95% CI: 0.070.52, P = 0.01). In 16 patients, therapy with azathioprine was initiated before or shortly after the index dilation; 7/16 underwent a new intervention compared to 48/67 of those without azathioprine (HR: 0.46, 95% CI: 0.211.03, P = 0.06). After adjustment for other variables, the association was even weaker (HR: 0.80, 95% CI: 0.292.18, P = 0.668). Sex, age at diagnosis, age at first dilation, balloon size, location of stricture, and treatment period did not influence outcome. Conclusions Smoking doubles the risk of recurrent stricture formation requiring a new intervention after index dilation. Maintenance therapy with azathioprine did not influence the subsequent course and need for a new intervention.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn's Disease

Anders Forss, Mark Clements, Par Myrelid, Hans Strid, Charlotte Soderman, Agnieszka Wagner, David Andersson, Fredrik Hjelm, Ola Olen, Jonas Halfvarson, Jonas F. Ludvigsson

Summary: This study demonstrates the long-term clinical effectiveness of ustekinumab in patients with active Crohn's disease, as well as its improvement in Health-related Quality of Life (HRQoL) measures.

DIGESTIVE DISEASES AND SCIENCES (2023)

Article Gastroenterology & Hepatology

The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study

Johanna Holmgren, Anna Froborg, Isabella Visuri, Jonas Halfvarson, Henrik Hjortswang, Pontus Karling, Par Myrelid, Ola Olen, Jonas F. Ludvigsson, Olof Grip

Summary: In patients with inflammatory bowel disease, the incidence rate of serious infection did not increase with the use of anti-TNF therapy and actually decreased more than 1 year after treatment initiation.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

Laurent Peyrin-Biroulet, Jean-Francois Rahier, Julien Kirchgesner, Vered Abitbol, Sebastian Shaji, Alessandro Armuzzi, Konstantinos Karmiris, Javier P. Gisbert, Peter Bossuyt, Ulf Helwig, Johan Burisch, Henit Yanai, Glen A. Doherty, Fernando Magro, Tamas Molnar, Mark Lowenberg, Jonas Halfvarson, Edyta Zagorowicz, Helene Rousseau, Cedric Baumann, Filip Baert, Laurent Beaugerie

Summary: The I-CARE study aims to evaluate the benefit-risk ratio of current therapies in IBD patients. It collected data from 10,206 patients and observed the treatment risks of anti-tumor necrosis factor and other biologic therapies, particularly the risks of cancer/lymphoma and serious infections. The results showed that different treatment regimens had varying effects on patients, and further research is needed to assess specific risks.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Bidirectional Mendelian Randomisation Analysis Provides Evidence for the Causal Involvement of Dysregulation of CXCL9, CCL11 and CASP8 in the Pathogenesis of Ulcerative Colitis

Jie Chen, Yajing Zhou, Yuhao Sun, Shuai Yuan, Rahul Kalla, Jing Sun, Jianhui Zhao, Lijuan Wang, Xuejie Chen, Xuan Zhou, Siqi Dai, Yu Zhang, Gwo-tzer Ho, Dajing Xia, Qian Cao, Zhanju Liu, Susanna C. Larsson, Xiaoyan Wang, Kefeng Ding, Jonas Halfvarson, Xue Li, Evropi Theodoratou, Jack Satsangi

Summary: This study identified 14 proteins associated with the risk of ulcerative colitis (UC) through the analysis of serum proteomic profiling data. Further analysis using Mendelian randomisation confirmed the causal relationship between two chemokines and the increased risk of UC. Additionally, a new protein associated with UC risk was identified. Reverse Mendelian randomisation analysis did not find any influence of genetic predisposition to UC on these three inflammation proteins.

JOURNAL OF CROHNS & COLITIS (2023)

Article Obstetrics & Gynecology

Previous pre-eclampsia, gestational diabetes mellitus and the risk of cardiovascular disease: A nested case-control study in Sweden

K. Hilden, A. Magnuson, S. Montgomery, E. Schwarcz, U. Hanson, D. Simmons, H. Backman

Summary: This study investigates the associations between pre-eclampsia, gestational diabetes mellitus (GDM), and cardiovascular disease (CVD). The results show that both pre-eclampsia and GDM are independent risk factors for later CVD. The association between pre-eclampsia and CVD is not modified by body mass index (BMI). Effective CVD preventive programs for high-risk women are urgently needed.

BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2023)

Article Medicine, General & Internal

Long-term risk of inflammatory bowel disease after endoscopic biopsy with normal mucosa: A population-based, sibling-controlled cohort study in Sweden

Jiangwei Sun, Fang Fang, Ola Olen, Mingyang F. Song, Jonas Halfvarson, Bjorn Roelstraete, Hamed Khalili, Jonas Ludvigsson

Summary: In this study, individuals who underwent endoscopic biopsy with normal mucosa were followed up for a median of 10 years. The study found that these individuals had an elevated risk of inflammatory bowel disease (IBD) for at least 30 years. These findings imply the presence of a substantial symptomatic period before the diagnosis of IBD and emphasize the importance of considering the long-term risk of IBD in patients with symptoms but normal mucosa on gastrointestinal investigation.

PLOS MEDICINE (2023)

Article Gastroenterology & Hepatology

Colectomy in patients with ulcerative colitis is not associated to future diagnosis of primary sclerosing cholangitis

Aiva Lundberg Bave, Ola Olen, Jonas Soederling, Jonas F. Ludvigsson, Annika Bergquist, Caroline Nordenvall

Summary: Colectomy in UC patients was not associated with a decreased risk of subsequent PSC. The observed differences in the risk of PSC development over calendar periods are likely due to changes in PSC-diagnosis and UC-treatment.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2023)

Article Gastroenterology & Hepatology

The Real-World Global Use of Patient-Reported Outcomes for the Care of Patients With Inflammatory Bowel Disease

Jamie M. Horrigan, Edouard Louis, Antonino Spinelli, Simon Travis, Bjorn Moum, Jessica Salwen-Deremer, Jonas Halfvarson, Remo Panaccione, Marla C. Dubinsky, Pia Munkholm, Corey A. Siegel

Summary: This study investigated the global use and barriers to using patient-reported outcomes (PROs) in clinical practice for inflammatory bowel disease (IBD). The majority of healthcare providers use PROs in clinical practice, but there are variations in which PROs are used and how they influence management. Barriers to using PROs include lack of familiarity, integration issues, and time constraints. Education about PROs and the use of an accepted set of PROs can help overcome these barriers and achieve global harmonization.

CROHNS & COLITIS 360 (2023)

Article Gastroenterology & Hepatology

Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels

Joel Thunberg, Olle Granno, Daniel Bergemalm, Carl Eriksson, Isabella Visuri, Michael Eberhardson, Jonas Halfvarson

Summary: This study examined the agreement between a point-of-care test (POCT) by ProciseDx and the in-house enzyme-linked immunosorbent assay (ELISA) for infliximab (IFX) quantification. The results showed good agreement between the two methods, supporting the use of ProciseDx's POCT for rapid IFX quantification.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2023)

Article Medicine, General & Internal

Long-term risk of arrhythmias in patients with inflammatory bowel disease: A population-based, sibling-controlled cohort study

Jiangwei Sun, Bjorn Roelstraete, Emma Svennberg, Jonas Halfvarson, Johan Sundstrom, Anders Forss, Ola Olen, Jonas F. Ludvigsson

Summary: This study found that patients with inflammatory bowel disease (IBD) have an increased risk of developing arrhythmias. This increased risk persists even 25 years after the diagnosis of IBD.

PLOS MEDICINE (2023)

Article Medicine, General & Internal

Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus

Ferdinando D'Amico, Virginia Solitano, Fernando Magro, Pablo A. Olivera, Jonas Halfvarson, David Rubin, Axel Dignass, Sameer Al Awadhi, Taku Kobayashi, Natalia Sousa Freitas Queiroz, Marta Calvo, Paulo Gustavo Kotze, Subrata Ghosh, Laurent Peyrin-Biroulet, Silvio Danese

Summary: As the patents for biologic originator drugs expire, biosimilars are emerging as cost-effective alternatives within healthcare systems. A global survey was conducted to shed light on physicians' knowledge, beliefs, practical approaches, and concerns related to biosimilar adoption. Based on the survey results, a consensus was reached on key statements covering biosimilar effectiveness, safety, indications, rationale, multiple switches, therapeutic drug monitoring, non-medical switching, and future perspectives. The consensus affirmed that biosimilars are equally effective and safe compared to originator drugs.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Gastroenterology & Hepatology

Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study

Isabella Visuri, Carl Eriksson, Sara Karlqvist, Byron Lykiardopoulos, Per Karlen, Olof Grip, Charlotte Soderman, Sven Almer, Erik Hertervig, Jan Marsal, Carolina Malmgren, Jenny Delin, Hans Strid, Mats Sjoberg, Daniel Bergemalm, Henrik Hjortswang, Jonas Halfvarson

Summary: This study assessed the long-term outcomes of vedolizumab in treating inflammatory bowel disease. The results showed that vedolizumab had high continuation rates and was associated with improvements in clinical outcomes, health-related quality of life measures, and inflammatory markers at 2 and 3 years after treatment initiation.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2023)

Article Gastroenterology & Hepatology

Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease

Archana Shubhakar, Bas C. Jansen, Alex T. Adams, Karli R. Reiding, Nicholas T. Ventham, Rahul Kalla, Daniel Bergemalm, Paulina A. Urbanowicz, Richard A. Gardner, Manfred IBD BIOM Consortium, Manfred Wuhrer, Jonas Halfvarson, Jack Satsangi, Daryl L. Fernandes, Daniel I. R. Spencer

Summary: This study investigated a composite serum N-glycomic biomarker to predict future disease course in newly diagnosed IBD patients. The biomarker showed a predictive capacity for treatment escalation in both the discovery and replication cohorts of patients.

JOURNAL OF CROHNS & COLITIS (2023)

Article Public, Environmental & Occupational Health

Prevalence and persistence of Neisseria meningitidis carriage in Swedish university students

Sall Olof, Eriksson Lorraine, A. Idosa Berhane, Persson Alexander, Magnuson Anders, Thulin Hedberg Sara, Sundqvist Martin, Olcen Per, Fredlund Hans, Stenmark Bianca, Sarndahl Eva, Molling Paula, Jacobsson Susanne

Summary: The aim of this study was to examine the prevalence, risk factors, distribution of meningococcal lineages, and persistence of N. meningitidis carriage among university students in Sweden. The carriage rate was 9.1%, with factors such as younger age, previous tonsillectomy, smoking, alcohol consumption, and attending parties, pubs, and clubs associated with higher carriage. Female gender and sharing a household with young children were associated with lower carriage. Further studies with longer follow-up times are recommended to investigate long-term carriage of N. meningitidis.

EPIDEMIOLOGY AND INFECTION (2023)

Article Gastroenterology & Hepatology

Eosinophilic esophagitis is associated with increased risk of later inflammatory bowel disease in a nationwide Swedish population cohort

Amiko M. Uchida, John J. Garber, Ashley Pyne, Kathryn Peterson, Bjorn Roelstraete, Ola Olen, Jonas Halfvarson, Jonas F. Ludvigsson

Summary: In this nationwide cohort study, EoE was found to be associated with a 3.5-fold increased risk of later IBD diagnosis, possibly due to genetic or early environmental risk factors.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2023)

No Data Available